Title: p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.
Authors: Banerjee, Audreesh; Koziol-White, Cynthia; Panettieri Jr, Reynold
Published In Curr Opin Pharmacol, (2012 Jun)
Abstract: COPD represents a major respiratory disorder, causing significant morbidity and mortality throughout the world. While therapies exist for COPD, they are not always effective, and many patients experience exacerbations and morbidity despite current therapies. Study of the molecular mechanisms involved in the underlying physiological manifestations of COPD has yielded multiple new targets for therapeutic intervention. In this review, we discuss signaling pathways involved in COPD pathogenesis and review clinical studies of p38 MAPK inhibitors, TNFα inhibitors, and IKK2 inhibitors as potential COPD therapies.
PubMed ID: 22365729
MeSH Terms: Animals; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use*; Humans; I-kappa B Kinase/antagonists & inhibitors*; I-kappa B Kinase/metabolism; Isoenzymes/antagonists & inhibitors; Isoenzymes/metabolism; Molecular Targeted Therapy*; Protein Kinase Inhibitors/therapeutic use*; Pulmonary Disease, Chronic Obstructive/drug therapy*; Pulmonary Disease, Chronic Obstructive/immunology; Pulmonary Disease, Chronic Obstructive/metabolism; Respiratory System/drug effects; Respiratory System/immunology; Respiratory System/metabolism; Signal Transduction/drug effects; Tumor Necrosis Factor-alpha/antagonists & inhibitors*; Tumor Necrosis Factor-alpha/metabolism; p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors*; p38 Mitogen-Activated Protein Kinases/metabolism